FIELD: pharmacology.
SUBSTANCE: invention relates to a compound of Formula (I) in free form or in the form of a pharmacologically acceptable salt
(I),
wherein L represents a relationship, (CH2)n, –CH(CH3)–, –O–(CH2)n–, –C(O)–, –C(O)–NH–(CH2)n–; n equals 1, 2 or 3; R1 is C3–C7cycloalkyl, optionally substituted once or more than once by a substituent independently selected from hydroxyl, halogen, C1–C3alkyl; or bridged C5–C10cycloalkyl, optionally substituted once or more than once by a substituent independently selected from hydroxyl and hydroxyC1–C3alkyl; R2 and R3 are independently selected from H, halogen and C1–C3alkyl; R4 is an N-containing heterocyclic non-aromatic ring, optionally containing one or more additional heteroatoms selected from N, O or S, where the specified ring is optionally substituted once or more than once by R7; each R7 is independently selected from C1–C3alkyl, hydroxyC1–C3alkyl, halogenC1–C3alkyl, C1–C3alkoxyC1–C3alkyl, halogenC1–C3alkoxyC1–C3alkyl, C2–C4alkynyl, cyanoC1–C3alkyl and (CH2)m–R8; m equals 0, 1, 2 or 3; R8 is selected from: 4–, 5– or 6-membered saturated or unsaturated non-aromatic heterocyclic ring containing one or more heteroatoms selected from N, O, or S, with the specified ring not necessarily replaced once or more than once by a substitute, independently selected from oxo SO2C1–C3alkyl and halogenC1–C3alkyl; or C3–C6cycloalkyl, optionally substituted once or more than once by halogen, which is used to suppress the activity of ALK–2 receptor; as well as to pharmaceutical compositions containing this compound, and the use of this compound in the treatment of heterotopic ossification and progressive ossifying fibrodysplasia.
EFFECT: this invention can be used in the treatment of heterotopic ossification and progressive ossifying fibrodysplasia.
18 cl, 19 dwg, 12 tbl, 93 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | 2022 |
|
RU2803084C1 |
| AMINOPYRIDINE DERIVATIVES AND APPLICATION THEREOF AS SELECTIVE ALK-2 INHIBITORS | 2017 |
|
RU2777979C2 |
| AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ALK-2 SELECTIVE INHIBITORS | 2023 |
|
RU2826177C1 |
| AZAINDAZOLE COMPOUNDS FOR USE IN INJURIES OF TENDONS AND/OR LIGAMENTS | 2017 |
|
RU2758256C2 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| AZABICYCLO{3,1,0}HEXANE DERIVATIVES USED AS DOPAMINE RECEPTOR D3 MODULATORS | 2005 |
|
RU2434011C2 |
| MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | 2019 |
|
RU2778294C2 |
| PHARMACEUTICAL COMPOUNDS | 2018 |
|
RU2767857C2 |
| NEW DERIVATIVE OF 3-AZABICYCLO[3.1.0]HEXANE AND USE THEREOF FOR MEDICAL PURPOSES | 2014 |
|
RU2701861C1 |
| PRODRUG OF THE AMINO ACID DERIVATIVE | 2017 |
|
RU2739318C2 |
